Show newer

These could be administered at least 4 months after the previous one, with a focus on people who have received a previous booster more than 6 months ago.

Currently authorised vaccines continue to be highly effective in reducing hospitalisations, severe disease & deaths.

🐦🔗: nitter.eu/ECDC_EU/status/15464

As a new wave is currently underway in Europe, with increasing rates of hospital and intensive care unit (ICU) admissions, it is critical that public health authorities now consider people between 60 and 79 as well as vulnerable persons of any age for a second booster.

🐦🔗: nitter.eu/ECDC_EU/status/15464

!

and @EMA_News update recommendations on additional doses of mRNA vaccines.

2nd booster doses should be considered for people 60-79 y.o. & those with medical conditions putting them at high risk of severe disease.

bit.ly/3AFWtQw

🐦🔗: nitter.eu/ECDC_EU/status/15464

RT @EU_Health: As we've seen over the last 2⃣ years, the situation can change very quickly

In April, we urged 🇪🇺 countries to improve preparedness & their readiness to respond, together

This means continued surveillance, testing & sustained vaccination


🐦🔗: nitter.eu/ECDC_EU/status/15464

Weekly country overview report is out now!

Cases rates among people aged 65+ increased in 22 of the 24 countries reporting data correspond to a 32% increase compared to the previous week at EU/EEA level, reaching 62.8% of the pandemic maximum.

bit.ly/2YB0pi4

🐦🔗: nitter.eu/ECDC_EU/status/15454

!
to our Rapid Risk Assessment on outbreak in the EU/EEA.

Read more about the case count, symptoms, measures to take and learn more about how to communicate about .

All that in a handy thread below ⬇️⬇️⬇️
RT @ECDC_Outbreaks: !
Rapid Risk Assessment: multi-country outbreak - first update.

Since early May 2022 and as of 7 July, 26 EU/EEA countries have reported 4 908 cases,…

🐦🔗: nitter.eu/ECDC_EU/status/15453

RT @Eurosurveillanc: @ECDC_EU @ECDC_Outbreaks @rki_de Rapid communication

A shift from travel-associated cases to autochthonous with Berlin as epicentre of outbreak in 🇩🇪, May─June 2022
👇🏽
eurosurveillance.org/content/1

@RuscherClaudia @BarteltLab @dr_uwetweets @rki_de

🐦🔗: nitter.eu/ECDC_EU/status/15453

RT @WHOUkraine: This week, WHO has carried out a mission to to provide technical support to the Government on cholera preparedness & response activities amidst the war w/@WHOFoundation support.

More👉facebook.com/WHOUkraine/posts/

🐦🔗: nitter.eu/ECDC_EU/status/15453

@HelenBranswell Hello @HelenBranswell!
Just a side note - you can change some of the graphs in the report to show the indicators broken down in different forms. There is also an epicurve based on symptoms onset!

🐦🔗: nitter.eu/ECDC_EU/status/15451

RT @HelenBranswell: 1. Short thread, based on data from @WHO_Europe & @ECDC:
The Euro outbreak continues to grow. Of +5200 cases reported here, 29 were women — which seems to be an increase. 15 health workers among cases; not clear if exposure was on the job.
monkeypoxreport.ecdc.europa.eu

🐦🔗: nitter.eu/ECDC_EU/status/15451

RT @EMA_News: will continue monitoring the monkeypox with @ECDC_EU, @euhealth and developers to help making medicines available for the prevention and treatment of 💊💉.

🐦🔗: nitter.eu/ECDC_EU/status/15451

RT @EMA_News: is working closely with @ECDC_EU, @EU_Health, and national public health authorities to identify the best approaches to vaccination in the 🇪🇺 and to deal with potential new waves of infections.

🐦🔗: nitter.eu/ECDC_EU/status/15451

RT @EMA_News: We are also in close contact with manufacturers of based on different platforms other than mRNA, especially adjuvanted protein vaccines.

🐦🔗: nitter.eu/ECDC_EU/status/15451

RT @EMA_News: Bivalent that combine two strains of SARS-CoV-2, one of which is an strain, appear to offer an even wider immune response.

🐦🔗: nitter.eu/ECDC_EU/status/15451

RT @EMA_News: Adapted : Preliminary from clinical trials indicate that adapted vaccines which incorporate an variant strain can increase and extend protection, when used as a .

🐦🔗: nitter.eu/ECDC_EU/status/15451

RT @EMA_News: The supplies of Imvanex are currently very limited in the 🇪🇺. While we fast-track the extension of Imvanex, Member States can use imported Jynneos from the 🇺🇸 as a temporary measure to vaccinate at-risk groups.

🐦🔗: nitter.eu/ECDC_EU/status/15451

RT @EMA_News: About : EMA’s human medicines committee is now reviewing data to extend the use of the smallpox Imvanex for monkeypox.

🐦🔗: nitter.eu/ECDC_EU/status/15451

RT @SoniaBoender: Out now @Eurosurveillanc 📰 eurosurveillance.org/content/1

We used routine emergency department data for syndromic of acute respiratory illness, to monitor the trends/timing/duration/magnitude and severity of illness by resp viruses incl &

🐦🔗: nitter.eu/ECDC_EU/status/15451

Show older
Mastodon

A Mastodon forum for the discussion of European Union matters. Not run by the EU. Powered by PleromaBot, Nitter and PrivacyDev.net.